Eight to twelve Gy linked to less retreatment than 4 Gy in cutaneous B-cell lymphoma
In previously unirradiated cutaneous B-cell lymphoma lesions, one-year freedom from retreatment was 75% after 4 Gy versus 100% after 8–12 Gy.
In previously unirradiated cutaneous B-cell lymphoma lesions, one-year freedom from retreatment was 75% after 4 Gy versus 100% after 8–12 Gy.
Across 32 experts, agreement fell to Dice 0.45 for elective nasopharyngeal targets despite identical starting GTV and OAR contours.
One-year local control was 96.1% with single-fraction SRS and 96.6% with fractionated SRS across 2,460 small brain metastases.
In oligometastatic hormone-sensitive prostate cancer, comprehensive SBRT plus intermittent ADT produced 78.2% five-year survival and 15.2% failure-free survival.
Five studies worth your time this week, spanning brain metastases, Merkel cell carcinoma, nutritional support, breast radiotherapy and prostate SBRT.
In 27 interviews, patients described rushed radiotherapy decisions, limited discussion of declining treatment, and insufficient preparation for treatment-related effects.
Across 11 studies, dose-escalated short-course rectal RT yielded variable complete responses, with grade ≥3 acute toxicity ranging from 0% to 62.5%.
In 203 patients with initially positive internal mammary nodes, doses above 60 Gy EQD2 did not improve five-year outcomes and increased dermatitis.
Among 12 patients, pancreatic SBRT with 30 Gy elective nodal irradiation produced one acute dose-limiting event and three grade 3 cholangitis events.
EXCERPT In 112 proton-treated low-grade glioma patients, 21% developed contrast-enhancing brain lesions, with modeling supporting increased periventricular and LET-dependent injury risk.
At 12 months, keloid recurrence was 6.9% with 13 Gy versus 23.3% with 9 Gy, but the overall randomized comparison was nonsignificant.
Patient-specific fine-tuning increased good cervical target segmentations from 23.7% to 55.8% across 430 CBCT scans in a seven-center evaluation.
A practical review summarizes hybrid and interstitial applicator selection, image-guided target delineation, cumulative dose constraints, and procedural management in gynecological brachytherapy.
In 15 paired basal breast cancers, genomic radiosensitivity index increased significantly in metastases, challenging assumptions of uniform radiosensitivity across tumor sites.
Depleting CCR8-positive regulatory T cells improved locoregional control and reversed resistance to radiotherapy plus anti-PD-1 in mouse head and neck cancer models.